Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Carlos Pavesio, EURETINA 2021: Fluocinolone Acetonide Insert – A Study

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 26th 2021

We were delighted to catch up with Carlos Pavesio (Moorfields Eye Hospital, London, UK), who shared details of his study to evaluate the safety and efficacy of the fluocinolone acetonide insert for the treatment of noninfectious uveitis.

Questions:

  1. What were the aims and design of your recent study? (00:31)
  2. What were the efficacy and safety outcome measures, and how well were these achieved? (02:02)
  3. What will be the next steps in the clinical development of the fluocinolone acetonide insert in this indication? (04:50)

Speaker Disclosure: Carlos Pavesio has no financial or non-financial relationships or activities to declare in relation to this interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed in coverage of EURETINA 2021.

 

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup